KR100549625B1 - 프로게스테론 및 에스트로겐을 기재로 하는 피임제 및이것의 제조 방법 - Google Patents
프로게스테론 및 에스트로겐을 기재로 하는 피임제 및이것의 제조 방법 Download PDFInfo
- Publication number
- KR100549625B1 KR100549625B1 KR1020027005258A KR20027005258A KR100549625B1 KR 100549625 B1 KR100549625 B1 KR 100549625B1 KR 1020027005258 A KR1020027005258 A KR 1020027005258A KR 20027005258 A KR20027005258 A KR 20027005258A KR 100549625 B1 KR100549625 B1 KR 100549625B1
- Authority
- KR
- South Korea
- Prior art keywords
- estradiol
- nomegestrol acetate
- progesterone
- nomegestrol
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
Description
포뮬레이션 | 정제 1개 당 MG | % |
에스트라디올 | 1.00 | 2.50 |
포비돈 | 6.00 | 15.00 |
락토스 | 33.00 | 82.50 |
이소프로필 알코올 | #6.14 | #15.35 |
탈염수 | #1.06 | #2.67 |
총 고형물 | 40.00 | 100.00 |
호르몬 파라미터 | 군 A(n=9) 1.5mg E2 + 0.625mg NOMAC | 군 B(n=10) 1.5mg E2 + 1.25mg NOMAC | 군 C(n=0) 1.5mg E2 + 2.5mg NOMAC | 군 D(n=9) 2.5mg NOMAC | p(ANOVA) | |
A,B,C 비교 | C 및 D 비교 | |||||
LH(mIU/ml) | 4.1 ±0.51 | 3.0 ±0.51 | 2.7 ±0.49 | 5.6 ±0.62 | 0.135 | 0.002 |
FSH(mIU/ml) | 6.2 ±0.42 | 6.6 ±0.52 | 5.4 ±0.75 | 7.6 ±0.28 | 0.318 | 0.019 |
프로게스테론 ng/ml | 0.11 ±0.031 | 0.07 ±0.024 | 0.03 ±0.009 | 0.07 ±0.014 | 0.068 | 0.056 |
에스트라디올 pg/ml | 62.0 ±7.90 | 57.6 ±4.53 | 47.2 ±5.61 | 31.9 ±3.91 | 0.225 | 0.043 |
호르몬 파라미터 | 주기 | NOMAC 1.25mg(n=3)1 | NOMAC 1.25+E2 1.5mg(n=10)2 |
LH(mIU/ml) | 대조군 | 4.5(4.0-5.0) | 7.1 ±0.82 |
처리된 군 | 3.1(2.6-3.7) | 3.0 ±0.51 | |
FSH(mIU/ml) | 대조군 | 4.3(4.0-4.5) | 6.6 ±0.28 |
처리된 군 | 3.3(2.5-4.2) | 6.9 ±0.48 | |
에스트라디올 pg/ml | 대조군 | 112.0(64.8-203.8) | 132.9 ±10.57 |
처리된 군 | 158.8(99.5-201.7) | 47.2 ±5.61 |
NOMAC의 용량(mg/일) | 0.625(n=35) | 1.25(n=33) | 2.5(n=34) | 5(n=41) |
처리 종료시의 평균 두께(mm) | 3.18(1.65) | 4.05(3.75) | 3.93(2.10) | 3.83(2.72) |
처리하의 두께의 평균 증가(mm) | 0.39(1.67) | 1.12(3.67) | 1.36(1.54) | 1.57(2.39) |
NOMAC의 용량(mg/일) | 0.625(n=32) | 1.25(n=33) | 2.5(n=34) | 5(n=40) |
자궁내막 부재 | 5(15.6) | 10(30.3) | 3(8.8) | 3(7.5) |
위축성 자궁내막 | 19(59.4) | 10(30.3) | 8(23.5) | 3(7.5) |
분비성 자궁내막 | 8(25.0) | 12(36.4) | 22(64.7) | 34(85.0) |
폴립(Polyp) | 0 | 1(3.0) | 1(2.9) | 0 |
Claims (17)
- (i) 0.3 mg 내지 3 mg의 에스트라디올 또는 에스트라디올 발러레이트, (ii) 0.1 mg 내지 1.25 mg의 노메게스트롤 아세테이트 및 (iii) 약제학적으로 허용되는 부형제를 포함하는 피임 조성물.
- 삭제
- 삭제
- 제 1항에 있어서, 0.3 mg 내지 1.25 mg의 노메게스트롤 아세테이트를 포함하는 피임 조성물.
- 삭제
- 제 1항에 있어서, 0.5 mg 내지 2 mg의 에스트라디올 또는 에스트라디올 발러레이트를 포함하는 피임 조성물.
- 제 1항에 있어서, 0.5 mg의 에스트라디올, 0.625 mg의 노메게스트롤 아세테이트 및 약제학적으로 허용되는 부형제를 포함하는 피임 조성물.
- 제 1항에 있어서, 1 mg의 에스트라디올, 0.625 mg의 노메게스트롤 아세테이트 및 약제학적으로 허용되는 부형제를 포함하는 피임 조성물.
- 제 1항에 있어서, 1.5 mg의 에스트라디올, 0.625 mg의 노메게스트롤 아세테이트 및 약제학적으로 허용되는 부형제를 포함하는 피임 조성물.
- 제 1항에 있어서, 2 mg의 에스트라디올, 0.625 mg의 노메게스트롤 아세테이트 및 약제학적으로 허용되는 부형제를 포함하는 피임 조성물.
- 제 1 항, 제 4항 및 제 6항 내지 제 10 항중의 어느 한 항에 있어서, 약제학적으로 허용되는 부형제가 소화 경로를 통하여 투여하기에 적절한 것인 피임 조성물.
- 제 1 항, 제 4항 및 제 6항 내지 제 10 항중의 어느 한 항에 있어서, 정제, 캡슐, 환제, 카세제 또는 분말 형태인 피임 조성물.
- 삭제
- (i) 0.3 mg 내지 3 mg의 에스트라디올 또는 에스트라디올 발러레이트, (ii) 0.1 mg 내지 1.25 mg의 노메게스트롤 아세테이트 및 (iii) 약제학적으로 허용되는 부형제를 포함하는 21 내지 28개의 정제를 포함하는 피임 제품.
- 제 14항에 있어서, 0.625 mg의 노메게스트롤 아세테이트를 포함하는 제품.
- 제 14항에 있어서, 1.25 mg의 노메게스트롤 아세테이트를 포함하는 제품.
- 제 14항에 있어서, 가약(placebo)만을 포함하는 0 내지 7개의 정제를 포함하는 제품.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRPCT/FR99/02587 | 1999-10-25 | ||
PCT/FR1999/002587 WO2001030355A1 (fr) | 1999-10-25 | 1999-10-25 | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020073333A KR20020073333A (ko) | 2002-09-23 |
KR100549625B1 true KR100549625B1 (ko) | 2006-02-08 |
Family
ID=9542725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027005258A KR100549625B1 (ko) | 1999-10-25 | 2000-10-24 | 프로게스테론 및 에스트로겐을 기재로 하는 피임제 및이것의 제조 방법 |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1227815A1 (ko) |
JP (1) | JP5484646B2 (ko) |
KR (1) | KR100549625B1 (ko) |
CN (1) | CN1205936C (ko) |
AP (1) | AP1707A (ko) |
AU (1) | AU784478B2 (ko) |
BR (1) | BR0014952A (ko) |
CA (1) | CA2388857C (ko) |
CR (1) | CR6627A (ko) |
CZ (1) | CZ301982B6 (ko) |
ES (1) | ES2565688T3 (ko) |
HK (2) | HK1048600A1 (ko) |
HU (1) | HU230467B1 (ko) |
IL (2) | IL149141A0 (ko) |
MX (1) | MXPA02004083A (ko) |
NO (1) | NO330885B1 (ko) |
NZ (1) | NZ518308A (ko) |
OA (1) | OA12071A (ko) |
RU (1) | RU2258512C2 (ko) |
WO (2) | WO2001030355A1 (ko) |
ZA (1) | ZA200203399B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754179B1 (fr) | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
KR100975350B1 (ko) * | 2002-11-29 | 2010-08-12 | 재단법인서울대학교산학협력재단 | 사람 락토페리신을 생산하는 형질전환 복제 소 및 이것의생산방법 |
BRPI0512991A (pt) * | 2004-07-07 | 2008-04-22 | Wyeth Corp | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto |
US8663681B2 (en) * | 2005-05-26 | 2014-03-04 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
CN103877059A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种醋酸诺美孕酮片及其制备工艺 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4390531A (en) | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
US4921843A (en) | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
US4628051A (en) | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
IE61236B1 (en) | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
EP0559240B1 (en) | 1987-09-24 | 2001-12-05 | Jencap Research Limited | Contraceptive packages containing oestrogen and progestin |
IE71203B1 (en) | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
IE62665B1 (en) | 1990-12-17 | 1995-02-22 | Akzo Nv | Contraceptive regimen |
US5532416A (en) | 1994-07-20 | 1996-07-02 | Monsanto Company | Benzoyl derivatives and synthesis thereof |
DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
FR2737411B1 (fr) * | 1995-08-01 | 1997-10-17 | Theramex | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
DE19529767A1 (de) | 1995-08-12 | 1997-02-13 | Huels Chemische Werke Ag | Amphiphile Verbindungen mit mehreren hydrophilen und hydrophoben Gruppen auf der Basis von Aminobernsteinsäurederivaten |
US5902914A (en) | 1995-08-14 | 1999-05-11 | Alliedsignal Inc. | Process for the preparation of halogenated alkanes |
AUPN479995A0 (en) | 1995-08-15 | 1995-09-07 | Leon Kruss Technology Pty Limited | Lightweight cementitious composition |
US5654494A (en) | 1995-08-18 | 1997-08-05 | Alliedsignal Inc. | Process for the manufacture of 1,1,1,2-tetrafluoroethane |
US5530167A (en) | 1995-08-21 | 1996-06-25 | Eastman Chemical Company | Process for the preparation of 1,4-butenediol |
US5820059A (en) | 1995-10-02 | 1998-10-13 | Nsk Ltd. | Retractor for seat belt |
DE19536742A1 (de) | 1995-10-02 | 1997-04-03 | Teves Gmbh Alfred | Wischblatt für eine Scheibenwischvorrichtung eines Fahrzeuges |
DE29515703U1 (de) | 1995-10-02 | 1996-02-08 | Foehl Artur | Drehantriebsvorrichtung für einen Gurtstraffer |
DE19536744A1 (de) | 1995-10-02 | 1997-04-03 | Teves Gmbh Alfred | Wischblatt mit auswechselbarem Wischgummi für einen Fahrzeugscheibenwischer |
DE19536745A1 (de) | 1995-10-02 | 1997-04-03 | Teves Gmbh Alfred | Wischblatt für eine Scheibenwischervorrichtung eines Fahrzeuges, insbesondere eines Kraftfahrzeuges |
EP0770338B1 (en) | 1995-10-23 | 2002-09-25 | Honda Access Corp. | Cap body of a helmet |
DE19540253C2 (de) | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
DE19549264A1 (de) | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
WO1997041868A1 (en) | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
GB9621990D0 (en) | 1996-10-22 | 1996-12-18 | Scotia Pharma Ltd | Use |
DE19705229C2 (de) | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
DE69827017T2 (de) | 1997-08-27 | 2006-03-09 | Ortho-Mcneil Pharmaceutical, Inc. | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung |
DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
WO1999013882A1 (en) | 1997-09-12 | 1999-03-25 | American Home Products Corporation | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
-
1999
- 1999-10-25 WO PCT/FR1999/002587 patent/WO2001030355A1/fr active Application Filing
-
2000
- 2000-10-24 WO PCT/FR2000/002952 patent/WO2001030358A1/fr not_active Application Discontinuation
- 2000-10-24 AU AU10335/01A patent/AU784478B2/en not_active Expired
- 2000-10-24 AP APAP/P/2002/002485A patent/AP1707A/en active
- 2000-10-24 EP EP00971488A patent/EP1227815A1/fr not_active Withdrawn
- 2000-10-24 OA OA1200200118A patent/OA12071A/fr unknown
- 2000-10-24 HU HU0203443A patent/HU230467B1/hu unknown
- 2000-10-24 CA CA2388857A patent/CA2388857C/fr not_active Expired - Lifetime
- 2000-10-24 BR BR0014952-7A patent/BR0014952A/pt not_active Application Discontinuation
- 2000-10-24 MX MXPA02004083A patent/MXPA02004083A/es active IP Right Grant
- 2000-10-24 CZ CZ20021426A patent/CZ301982B6/cs not_active IP Right Cessation
- 2000-10-24 RU RU2002113654/15A patent/RU2258512C2/ru active
- 2000-10-24 CN CNB008147868A patent/CN1205936C/zh not_active Expired - Lifetime
- 2000-10-24 KR KR1020027005258A patent/KR100549625B1/ko active IP Right Grant
- 2000-10-24 EP EP08168565.3A patent/EP2020236B1/fr not_active Expired - Lifetime
- 2000-10-24 IL IL14914100A patent/IL149141A0/xx active IP Right Grant
- 2000-10-24 JP JP2001532776A patent/JP5484646B2/ja not_active Expired - Lifetime
- 2000-10-24 ES ES08168565.3T patent/ES2565688T3/es not_active Expired - Lifetime
- 2000-10-24 NZ NZ518308A patent/NZ518308A/en not_active IP Right Cessation
-
2002
- 2002-04-15 IL IL149141A patent/IL149141A/en active Protection Beyond IP Right Term
- 2002-04-24 CR CR6627A patent/CR6627A/es not_active Application Discontinuation
- 2002-04-25 NO NO20021948A patent/NO330885B1/no not_active IP Right Cessation
- 2002-04-29 ZA ZA200203399A patent/ZA200203399B/en unknown
-
2003
- 2003-02-06 HK HK03100876.6A patent/HK1048600A1/zh unknown
-
2009
- 2009-07-30 HK HK09107002.2A patent/HK1129564A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7799771B2 (en) | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation | |
EP0803250B1 (en) | Controlled release of steroids from sugar coatings | |
US9084796B2 (en) | Hormonal composition and its use | |
HU223781B1 (hu) | Új cukorbevonat készítmény préselt gyógyszertablettákon való alkalmazásra | |
US6906049B1 (en) | Contraceptive medicine based on a progestational agent and an oestrogen and preparation method | |
KR100549625B1 (ko) | 프로게스테론 및 에스트로겐을 기재로 하는 피임제 및이것의 제조 방법 | |
JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
CA2368370C (en) | The use of dienogest in high dosages | |
EP3954364A1 (en) | New modified release oral contraceptive composition | |
KR20030043797A (ko) | 호르몬 조성물 | |
PL203596B1 (pl) | Zastosowanie kompozycji zawieraj acej estradiol i octan nomegestrolu oraz produkt antykoncepcyjny |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130118 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140123 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150122 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160121 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170120 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190109 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20200121 Year of fee payment: 15 |